Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Asahi Ito"'
Autor:
Takuto Tachita, Masaki Ri, Sho Aoki, Arisa Asano, Takashi Kanamori, Haruhito Totani, Shiori Kinoshita, Yu Asao, Tomoko Narita, Ayako Masaki, Asahi Ito, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Multiple myeloma (MM) is an incurable B‐cell malignancy often accompanied by profound immunodeficiency. Lenalidomide (Len) is an immunomodulatory drug that exerts promising therapeutic effects on MM through the immune system. However, pred
Externí odkaz:
https://doaj.org/article/5be8624e698c4954a681a98d8ab053ef
Autor:
Tomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, Hiroya Hashimoto, Nozomi Nishitarumizu, Yoko Nakanishi, Yukiyasu Kato, Akimi Kawai, Naohiro Matsunaga, Toru Ebina, Tomoyuki Nakamura, Yoshiaki Marumo, Kana Oiwa, Shiori Kinoshita, Tomoko Narita, Asahi Ito, Atsushi Inagaki, Masaki Ri, Hirokazu Komatsu, Takashi Aritsu, Shinsuke Iida
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13135-13144 (2023)
Abstract Background The recently developed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions,
Externí odkaz:
https://doaj.org/article/250baa990edc4fb8b1c546d09c22e6aa
Autor:
Tomotaka Suzuki, Rui Yokomori, Takaomi Sanda, Takaki Kikuchi, Yoshiaki Marumo, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Asahi Ito, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
We report a 69-year-old female who was a human T-cell leukemia virus type 1 carrier and exhibited a unique clinical course of developing three hematological malignancies within a short period: diffuse large B-cell lymphoma (DLBCL), chronic myelomonoc
Externí odkaz:
https://doaj.org/article/8aba716dd1a04644967bae0b971ebc08
Autor:
Hiroaki Hiramatsu, Kisato Nosaka, Shigeru Kusumoto, Nobuaki Nakano, Ilseung Choi, Makoto Yoshimitsu, Yoshitaka Imaizumi, Michihiro Hidaka, Hidenori Sasaki, Junya Makiyama, Eiichi Ohtsuka, Tatsuro Jo, Masao Ogata, Asahi Ito, Kentaro Yonekura, Hiro Tatetsu, Takeharu Kato, Toshiro Kawakita, Youko Suehiro, Kenji Ishitsuka, Shinsuke Iida, Takaji Matsutani, Hiroyoshi Nishikawa, Atae Utsunomiya, Ryuzo Ueda, Takashi Ishida
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/7a719b715c4f446799368076060e4e23
Autor:
Shinya Hagiwara, Shigeru Kusumoto, Asahi Ito, Ayako Masaki, Kazuhide Shiraga, Takuto Tachita, Kentaro Hirade, Kana Oiwa, Tomotaka Suzuki, Shiori Kinoshita, Masaki Ri, Yasuhiko Ito, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida
Publikováno v:
eJHaem, Vol 2, Iss 2, Pp 285-290 (2021)
Abstract A 15‐year‐old male was diagnosed with acute myeloid leukemia with t(6;9)(p23;q34), a chimeric DEK‐NUP214 fusion gene. He underwent allogeneic bone marrow transplantation (allo‐BMT) from an unrelated volunteer donor at first molecular
Externí odkaz:
https://doaj.org/article/a35732add6134cf3a015d97342e02613
Autor:
Norio Tanaka, Seiichi Mori, Kazuma Kiyotani, Yuki Ota, Osamu Gotoh, Shigeru Kusumoto, Nobuaki Nakano, Youko Suehiro, Asahi Ito, Ilseung Choi, Eiichi Ohtsuka, Michihiro Hidaka, Kisato Nosaka, Makoto Yoshimitsu, Yoshitaka Imaizumi, Shinsuke Iida, Atae Utsunomiya, Tetsuo Noda, Hiroyoshi Nishikawa, Ryuzo Ueda, Takashi Ishida
Publikováno v:
Haematologica, Vol 107, Iss 10 (2022)
In order to identify genomic biomarkers for the outcome of mogamulizumab-containing treatment, an integrated molecular analysis of adult T-cell leukemia/lymphoma (ATL) was conducted on 64 mogamulizumab-naïve patients. Among driver genes, CCR4 and CC
Externí odkaz:
https://doaj.org/article/87b586d60b8342499a82f5af97ec17be
Autor:
Takafumi Nakayama, Yoshiko Oshima, Shigeru Kusumoto, Junki Yamamoto, Satoshi Osaga, Haruna Fujinami, Takaki Kikuchi, Tomotaka Suzuki, Haruhito Totani, Shiori Kinoshita, Tomoko Narita, Asahi Ito, Masaki Ri, Hirokazu Komatsu, Kazuaki Wakami, Toshihiko Goto, Tomonori Sugiura, Yoshihiro Seo, Nobuyuki Ohte, Shinsuke Iida
Publikováno v:
eJHaem, Vol 1, Iss 2, Pp 498-506 (2020)
Abstract We investigated the incidence of cardiotoxicity, its risk factors, and the clinical course of cardiac function in patients with malignant lymphoma (ML) who received a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regime
Externí odkaz:
https://doaj.org/article/87ae7445493b4183952f1ca81d57c702
Autor:
Asahi Ito, Yui Suzuki, Ayako Masaki, Shinichiro Yoshida, Hitoshi Suzushima, Shigeki Takemoto, Atae Utsunomiya, Toshihiko Ishii, Masanori Hiura, Takeshi Takahashi, Satoshi Yurimoto, Hiroshi Inagaki, Akimichi Morita, Shinsuke Iida, Takashi Ishida
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 2, Iss 4, Pp 102-107 (2019)
Abstract Purpose Skin disorders demonstrate highly variable phenotypical and histopathological features. Mogamulizumab, a humanized anti‐CC chemokine receptor 4 monoclonal antibody indicated for the treatment of adult T‐cell leukemia‐lymphoma,
Externí odkaz:
https://doaj.org/article/1b8fc13cc8ab42f4ad0fd3df134da49b
Autor:
Shiori Kinoshita, Takashi Ishida, Asahi Ito, Tomoko Narita, Ayako Masaki, Susumu Suzuki, Takashi Yoshida, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Norio Shimizu, Hiroshi Inagaki, Taruho Kuroda, Arne Scholz, Ryuzo Ueda, Takaomi Sanda, Shinsuke Iida
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/positive transcription elongation factor b. It has entered phase I clinical studies. Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leuk
Externí odkaz:
https://doaj.org/article/5d778fa3591e41a1a5a21debea8accc7
Autor:
Takashi Yoshida, Masaki Ri, Shiori Kinoshita, Tomoko Narita, Haruhito Totani, Reham Ashour, Asahi Ito, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0196780 (2018)
Bortezomib (Btz) is an active agent used to treat multiple myeloma (MM). Not all patients who receive Btz-containing therapy show a favorable response. Interaction of cellular adhesion molecules with MM and bone marrow stromal cells is crucial for th
Externí odkaz:
https://doaj.org/article/d477ca8d874d486ca4a3f4e5f8141973